News

30.06.2022

Meet Michael Zehringer, Team Lead Stability

Dedication and expertise are key qualities necessary to provide flexible solutions to our customers, and we are lucky to have...

14.06.2022

Acino signs exclusive license agreement with Bioprojet for treatment of narcolepsy and obstructive sleeping apnoea (OSA)

This agreement strengthens Acino’s position in the Central Nervous System (CNS) therapeutic area and paves the way for greater patient...

23.05.2022

Acino committed to expansion and localisation

25.04.2022

Estonia solar panel project

Acino has recently installed solar panels at its facility in Estonia. This move aims to reduce the company’s carbon footprint...

19.04.2022

Acino achieves Level 1 B-BBEE status in South Africa for the third year running

For the third year running, Acino has attained Level 1 B-BBEE status in South Africa. The Broad Based Black Economic...

12.04.2022

Acino and Batterjee Pharma sign partnership agreement to support Saudi Arabia’s Health Sector Transformation Programmme

The agreement between Acino and Batterjee covers the licensing, manufacturing, and supply of select Acino products across the Kingdom, based...

06.04.2022

Acino and Alpha Pharma team up to further the goals of Saudi Arabia’s Health Sector Transformation Programme

The agreement between Acino and Alpha Pharma covers the licensing, manufacturing, and supply of select Acino products across the Kingdom,...

30.03.2022

Acino strengthens operations in Saudi Arabia following sustained growth in the Middle East and Africa

Swiss pharma company plans to bring high-quality affordable medicines to patients in the kingdom, as part of its ongoing global...

16.03.2022

Resilience of the Ukrainian colleagues

At Acino, we express our unwavering support for our colleagues, patients and customers in Ukraine, many of whom continue to...